Atlas Trials

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Clinical trial NCT05020769 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05020769
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2022-01-06
Primary completion
2025-12-01
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.